facebook pixel
chevron_right Health
transparent
Novartis eye drug works at less frequent dosing than rival's
Novartis eye drug RTH258 works as well as a rival product from Regeneron and at less frequent dosing in clinical trials, the Swiss drugmaker said on Tuesday, boosting its shares. This was achieved with over half the patients dosed every 12 weeks compared to every eight weeks with Eylea. Novartis shares rose 0.8 percent by 0826 GMT, outpacing a 0.2 percent gain in the Stoxx European health care sector index.
For the best experience use Awesummly app on your Android phone
Awesummly Chrome Extension Awesummly Android App